BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » cynata » Page 2

U.S. Patent Granted for Cynata Cymerus™ Technology

September 26, 2017 By Cade Hildreth (CEO) Leave a Comment

U.S. Patent for Cynata's Cymerus Technology

Melbourne, Australia; 27 September 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has granted a patent covering aspects of Cynata’s proprietary Cymerus™ mesenchymal stem cell technology.

Cymerus PatentThe patent entitled “A method of making primate cells expressing apelin receptor that have mesangioblast potential” covers certain proprietary methods relating to the platform’s ability to efficiently manufacture mesenchymal stem cells at scale. The patent is owned by the University of Wisconsin–Madison’s Wisconsin Alumni Research Foundation (WARF) and is among the intellectual property licensed exclusively from WARF to Cynata.

“We are delighted that the USPTO has granted this patent, building further strength in Cynata’s comprehensive patent portfolio”, said Dr Ross Macdonald, Cynata’s Chief Executive Officer. “Our proprietary Cymerus stem cell manufacturing technology enables the scalable manufacture of consistent, high-quality mesenchymal stem cell therapeutic products targeting a range of devastating diseases worldwide.”

The inventors named on the patent are Dr Maxim Vodyanyk and Professor Igor Slukvin, founders, advisors and shareholders of Cynata.

The patent has an expiration date of 1 February 2028. [Read more…]

Filed Under: iPS Cells, MSCs Tagged With: Cymerus, cynata, patent

Positive Data from Cynata MSCs in Second Preclinical Asthma Study

August 23, 2017 By Cade Hildreth (CEO) Leave a Comment

Cynata 2nd Preclinical Asthma Study
  • Clear efficacy data for Cynata’s proprietary Cymerus™ MSCs in second preclinical study in a clinically-relevant model of asthma
  • Cymerus MSCs caused significantly greater reduction of airway hyperresponsiveness compared to corticosteroid treatment
  • Data suggest Cymerus MSCs can be administered alone or in combination with corticosteroids to treat the airway hyperresponsiveness associated with asthma
  • Completion of this study will further advance the path towards clinical trials

Cynata TherapeuticsMELBOURNE, Australia, Aug. 23, 2017 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to announce further highly promising data supporting the efficacy of its proprietary Cymerus™ mesenchymal stem cells (MSCs) in a second preclinical asthma study.

The study was conducted under the supervision of Associate Professor Samuel and Dr Simon Royce of the Monash Lung Biology Network,1 focusing on the effects of CymerusTM MSCs in combination with or in comparison to the corticosteroid dexamethasone, which is commonly used to treat exacerbations of asthma in human patients. The study used a well-established mouse model of chronic allergic airways disease that closely resembles asthma in humans. This part of the study focused on airway hyperresponsiveness (AHR), which is a key clinical manifestation of asthma. [Read more…]

Filed Under: MSCs Tagged With: asthma, cynata, preclinical

Cynata Files New Patent Application for Cymerus™ Stem Cell Technology in Oncology

June 21, 2017 By Cade Hildreth (CEO) Leave a Comment

  • Application filed with IP Australia would expand patent estate to immunotherapy
  • Creates new opportunities in the growing field of immunotherapy and reinforces a position in oncology

[Read more…]

Filed Under: iPS Cells, MSCs Tagged With: Cymerus, cynata

Patient Treatment Commences in Cynata’s World First Clinical Trial (CYP-001)

May 16, 2017 By Cade Hildreth (CEO) 1 Comment

Cynata CYP-001 Clinical Trial
  • First patient with steroid resistant acute graft-versus-host disease (GvHD) treated in Cynata’s phase 1 clinical study of its mesenchymal stem cell (MSC) product, CYP-001
  • World first clinical trial using a MSC therapeutic product derived from an induced pluripotent stem cell sourced from a single blood donation from one donor
  • Transition into active clinical trials cements Cynata’s world leading position in the development and commercialisation of second generation stem cell products
  • Partnership with Fujifilm for the commercialisation of CYP-001; trial commencement accelerates this target

[Read more…]

Filed Under: iPS Cells, MSCs Tagged With: clinical trial, cynata, CYP-001, MSC

Cynata Files for New Patent for Oncology Applications

April 12, 2017 By Cade Hildreth (CEO) Leave a Comment

Cynata Files for New Patent for Oncology Applications

• Further patent application filed for oncology applications

• Patents strengthen the Company’s intellectual property and solidifies its focus in the field of oncology

• Patent filing forms a key part of the Company’s strategy to protect its platform

[Read more…]

Filed Under: iPS Cells, MSCs Tagged With: Cymerus, cynata, oncology

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.